electroCore Announces Second Quarter 2023 Financial Results
Record second quarter 2023 net sales of $3.6 million, an increase of approximately 65% over second quarter 2022
ROCKAWAY, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company and wellness company, today announced second quarter 2023 financial results and provided an operational update.
Second Quarter 2023 and Recent Highlights
- Record revenue of $3.6 million, an increase of approximately 65% over second quarter 2022
- TAC-STIM™ Non-Invasive Vagal Nerve Stimulation has been selected for inclusion in the Air Force Research Laboratories (AFRL) Real-Time Assessing and Augmenting Cognitive Performance in Extreme Environments Project (A2PEX)
- Announced gammaCore™ Non-Invasive Vagal Nerve Stimulation has been selected for a study funded by the National Football League (NFL) and National Football League Players Association (NFLPA) on Alleviating Concussion Symptoms
- Announced publication of a peer reviewed manuscript indicating gammaCore™ Non-Invasive Vagal Nerve Stimulation improves attention and memory in patients with posttraumatic stress disorder (PTSD)
- Raised net proceeds of approximately $7.5 million in a registered direct public offering and concurrent private placement to institutional and accredited investors, and officers and directors.
“We recorded record revenue of $3.6 million during the second quarter of 2023, an increase of 65% over the second quarter of 2022,” stated Dan Goldberger, Chief Executive Officer of electroCore. “This is our third consecutive quarter of significant sequential growth fueled by our prescription gammaCore business as well as our new products, Truvaga™, and TAC-STIM.”
Second Quarter 2023 Financial Results
For the quarter ended June 30, 2023, electroCore reported net sales of $3.6 million compared to $2.2 million during the same period of 2022, which represents an approximately 65% increase over the prior year. The increase of $1.4 million is due to an increase in net sales across major U.S. channels including the sale of our prescription gammaCore products in all channels, and revenue from the sales of our nonprescription performance TAC-STIM and Truvaga wellness products.
| (in thousands) | Three months ended June 30, | Three months ended June 30, | % Change | Six months ended June 30, | Six months ended June 30, | % Change | ||||||||||||||||
| Channel | 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||
| Rx gammaCore – Department of Veteran Affairs and Department of Defense | $ | 2,081 | $ | 1,190 | 75 | % | $ | 3,786 | $ | 2,430 | 56 | % | ||||||||||
| Rx gammaCore – U.S. Commercial | 441 | 465 | -5 | % | 871 | 741 | 18 | % | ||||||||||||||
| Outside the United States | 424 | 467 | -9 | % | 834 | 772 | 8 | % | ||||||||||||||
| Truvaga | 290 | — | — | 437 | — | — | ||||||||||||||||
| TAC-STIM | 311 | — | — | 399 | — | — | ||||||||||||||||
| Other | 4 | 35 | -89 | % | 4 | 113 | -96 | % | ||||||||||||||
| $ | 3,551 | $ | 2,157 | 65 | % | $ | 6,331 | $ | 4,056 | 56 | % | |||||||||||
Gross profit for the second quarter of 2023 was $3.0 million as compared to $1.8 million for the second quarter of 2022. Gross margin for the second quarter of 2023 was 84% as compared to 83% in the second quarter of 2022.
Total operating expenses in the second quarter of 2023 were approximately $8.0 million as compared to $7.6 million in the second quarter of 2022.
Research and development expense in the second quarter of 2023 was $1.2 million as compared to $1.3 million in the second quarter of 2022. This decrease was due to cost cutting measures offset by targeted investments to support future iterations of our therapy delivery platform, including use of our intellectual property around the delivery of smart phone-integrated and smart phone-connected non-invasive therapies.
Selling, general and administrative expense in the second quarter of 2023 was $6.8 million as compared to $6.3 million in the second quarter of 2022.This increase was due to continued targeted investments in sales and marketing to support our commercial efforts, offset by decreases in insurance and stock-based compensation expense.
GAAP net loss in the second quarter of 2023 was $4.9 million compared to the $5.3 million net loss in the second quarter of 2022.
Adjusted EBITDA net loss in the second quarter of 2023 was $4.5 million as compared to a net loss of $4.9 million in the second quarter of 2022.
The Company defines adjusted EBITDA net loss as GAAP net loss, adjusted to exclude non-operating gains/losses, depreciation and amortization, stock-based compensation expense, severance and other related charges, inventory reserve charges, legal fees associated with stockholders’ litigation, and benefit from income taxes. A reconciliation of GAAP net loss to non-GAAP adjusted EBITDA net loss has been provided in the financial statement tables included in the press release.
Net cash used in operating activities in the quarter ended June 30, 2023, was approximately $3.3 million as compared to $3.2 million in the second quarter of 2022. This increase is primarily due to our investment in product evolution expenditures.
Cash, cash equivalents and restricted cash at June 30, 2023 totaled approximately $8.7 million, as compared to approximately $18.0 million as of December 31, 2022. Subsequent to June 30, 2023, the Company raised net proceeds of approximately $7.5 million through a registered direct offering and concurrent private placements priced “at the market” under Nasdaq rules. With this recent capital raise, the Company had a pro forma cash balance of $16.2 million as of June 30, 2023.
Full Year 2023 Outlook
The Company reiterates its revenue guidance of $14.0 million – $15.0 million for calendar year 2023.
The Company expects cash usage will continue to decrease in coming quarters as revenues increase, the Company reduces R&D expenses and continues to rationalize other operating expenses. Therefore, the Company expects net cash usage to decrease significantly through the year.
Webcast and Conference Call Information
electroCore’s management team will host a conference call today, August 9, 2023, beginning at 4:30 PM EDT.
Investors interested in listening to the conference call, or webcast may dial 877-407-8835 for domestic callers or 201-689-8779 for international callers, using Conference ID: 13739200, or by connecting to the Web: electroCore Earnings Webcast. An archived webcast of the event will be available on the “Investors” section of the company’s website at: www.electrocore.com.
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.
Forward-Looking Statements
This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about expectations for revenue for 2023, cash resources through 2024 and beyond, electroCore’s business prospects and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; business prospects around its Truvaga wellness and TAC-STIM human performance offerings and other new products and markets, and other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “believes,” “intends,” and other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, TAC-STIM™, and Truvaga™, the potential impact and effects of COVID-19 on the business of electroCore, electroCore’s results of operations and financial performance, inflation and currency fluctuations, and any expectations electroCore may have with respect thereto, competition in the industry in which electroCore operates and overall economic and market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the SEC available at www.sec.gov.
Contact:
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com